Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The CHECKMATE-67T trial showed a 24% response rate for subcutaneous Opdivo ...

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously approved adult, solid tumor Opdivo ...

Nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) was approved by the FDA for subcutaneous injection across approved solid tumor indications for nivolumab (Opdivo). The FDA granted approval to ...

Nivolumab plus hyaluronidase-nvhy is approved for subcutaneous injection across all solid tumor indications previously approved for nivolumab. The CheckMate-67T trial showed subcutaneous nivolumab's ...

This approval makes it the first and only subcutaneously administered PD-1 inhibitor. Subcutaneous nivolumab is approved in all previously approved solid tumor indications of the intravenous (IV) ...

FRIDAY, Jan. 3, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use for most previously ...

Mol Cancer Ther (2025) 24 (1): 93–104.

The FDA granted approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a subcutaneous version of Opdivo, to treat patients with solid tumors. It is approved as monotherapy, monotherapy ...

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myelomaSarclisa SC formulation added to ...